ALK fears politicians will force pharma industry to foot pandemic bill

The pandemic was a massive expense for governments around the world, and the allergy firm’s CEO Carsten Hellmann sees signs that some governments might force the pharma industry to pick up the tab.

Carsten Hellmann, CEO of ALK | Photo: Gregers Tycho/ERH

ALK suspects that governments in Europe are currently investigating how to offset the huge expenses incurred by the Covid-19 pandemic.

The allergy firm’s chief executive, Carsten Hellmann, is fearing that some officials might make the life science industry foot part of the bill through increased taxation in some of Europe’s most important markets.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs